What is the recommended management for a child with multisystem inflammatory syndrome (MIS‑C) presenting with cytokine storm?

Management of MIS-C with Cytokine Storm

For a child with MIS-C presenting with cytokine storm, initiate combination therapy with IVIG 2 gm/kg PLUS methylprednisolone 1-2 mg/kg/day IV immediately, and if refractory to this first-line treatment, escalate to high-dose methylprednisolone (10-30 mg/kg/day) or high-dose anakinra (>4 mg/kg/day). 1

First-Line Immunomodulatory Treatment

The American College of Rheumatology 2021 guidelines provide the definitive treatment algorithm for MIS-C with cytokine storm:

Initial Therapy

• IVIG: 2 gm/kg based on ideal body weight 1

  • Assess cardiac function and fluid status before administration
  • If cardiac dysfunction present, divide dose over 2 days (1 gm/kg daily)
  • Critical pitfall: Do NOT give a second dose of IVIG for refractory disease—this increases risk of hemolytic anemia and volume overload 1

• PLUS Methylprednisolone: 1-2 mg/kg/day IV 1

  • Use as adjunctive therapy in patients with shock and/or organ-threatening disease
  • Also indicated for patients with concerning features even without shock: ill appearance, highly elevated BNP, unexplained tachycardia 1

Rationale for Combination Therapy

The evidence strongly supports upfront combination therapy rather than IVIG monotherapy. Children with MIS-C and myocarditis treated with IVIG plus methylprednisolone had faster cardiac recovery and shorter ICU stays compared to IVIG alone 1. MIS-C patients show higher rates of IVIG resistance compared to historical Kawasaki disease cohorts, justifying early glucocorticoid use 1.

Intensification for Refractory Disease

Refractory disease = persistent fevers and/or ongoing significant end-organ involvement despite initial treatment 1

Choose ONE of the following:

Option 1: High-Dose Methylprednisolone (10-30 mg/kg/day IV) 1

• Particularly effective for children in shock requiring multiple inotropes/vasopressors
• Has been used safely in KD and successfully in MIS-C with shock
• Shortens duration of shock in sepsis

Option 2: High-Dose Anakinra (>4 mg/kg/day IV or SC) 1

• Consider for patients with features of macrophage activation syndrome
• Use as steroid-sparing agent if contraindications to prolonged glucocorticoids exist
• Safe in pediatric hyperinflammatory syndromes and active infection
• Monitor liver function tests during anakinra therapy 1

Anticoagulation Management

Low-dose aspirin (3-5 mg/kg/day; maximum 81 mg/day) should be started in all MIS-C patients 1

• Continue until platelet count normalizes AND normal coronary arteries confirmed at ≥4 weeks
• Contraindications: active bleeding, significant bleeding risk, platelets ≤80,000/µl
• Use antacid prophylaxis

Escalate to Therapeutic Anticoagulation if:

• Documented thrombosis OR ejection fraction <35%: therapeutic enoxaparin until ≥2 weeks post-discharge 1
• Coronary artery z-score ≥10.0: therapeutic anticoagulation indefinitely 1
• Coronary artery z-score 2.5-10.0: low-dose aspirin only 1

Treatment Duration and Tapering

• Serial laboratory testing and cardiac assessment must guide tapering decisions 1
• Expect 2-3 weeks or longer of immunomodulatory treatment to avoid rebound inflammation 1
• Do not rush tapering—MIS-C requires prolonged courses compared to typical KD

Key Clinical Pitfalls to Avoid

1. Do NOT give second dose of IVIG for refractory disease—escalate to high-dose steroids or anakinra instead 1
2. Do NOT use tocilizumab routinely—randomized trials in adults with COVID-19 pneumonia showed no benefit 1
3. Assess volume status before IVIG—these patients have larger body sizes than typical KD patients and are at higher risk for volume overload 1
4. Do NOT delay glucocorticoids in patients with shock or organ-threatening disease—combination therapy is superior to IVIG monotherapy 1

Supportive Care Essentials

• Hemodynamic stabilization with volume repletion (for GI losses) and cardiac pressors (epinephrine preferred) 2
• Continuous cardiac monitoring
• Consider cytokine filtration (oXiris®) with CRRT in severely ill children requiring mechanical ventilation and vasopressors—case reports show marked improvement within 24 hours 3

The evidence base for this approach comes from high-consensus ACR guidelines 1 incorporating experience from KD management, emerging MIS-C data, and adult COVID-19 trials. While some recent research suggests corticosteroid monotherapy may be non-inferior to combination therapy 4, the established ACR guidelines with moderate-to-high consensus support combination IVIG plus steroids for cytokine storm presentations, which represents the safest approach for severe disease.